The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health
Open accessAbstract
Aspergillus fumigatus, a ubiquitously distributed opportunistic pathogen, is the global leading cause of aspergillosis and causes one of the highest numbers of deaths among patients with fungal infections [1]. Invasive aspergillosis is the most severe manifestation with an overall annual incidence up to 10% in immunosuppressed patients, whereas chronic pulmonary aspergillosis affects about 3 million, primarily immunocompetent, individuals each year [2]. Three triazole antifungals, namely itraconazole, voriconazole, and posaconazole, are recommended first-line drugs in the treatment and prophylaxis of aspergillosis [3]. However, azole resistance in A. fumigatus isolates is increasingly reported with variable prevalence in Europe, the United States, South America, China, Japan, Iran, and India [4]–[9]. For example, about 10% of strains of A. fumigatus from the Netherlands are itraconazole resistant, and in the United Kingdom, the frequency increased from 0%–5% during 2002–2004 to 17%–20% in 2007–2009 [10]–[13]. In the ARTEMIS global surveillance program involving 62 medical centers, 5.8% of A. fumigatus strains showed elevated MICs to one or more triazoles [5]. Similarly, the prospective SCARE (Surveillance Collaboration on Aspergillus Resistance in Europe) study involving 22 medical centers in 19 countries identified an overall prevalence of 3.4% azole resistance. Azole-resistant A. fumigatus (ARAF) ranged from 0% to 26% among the 22 centres and was detected in 11 (57.9%) of the 19 participating European countries [4 and P.E. Verweij, personal communication]. Interestingly, almost half (48.9%) of the ARAF isolates from the SCARE network in European countries were resistant to multiple azoles and harbored the TR34/L98H mutation in the cyp51A gene [4 and P.E. Verweij, personal communication]. Indeed, multi-azole resistance in A. fumigatus due to the TR34/L98H mutations has become an emerging problem in both Europe and Asia and has been associated with high rates of treatment failures [12]–[14]. Azole antifungal drugs inhibit the ergosterol biosynthesis pathway, specifically the cytochrome p450 sterol 14-α-demethylase encoded by the cyp51A gene, which leads to depletion of ergosterol and accumulation of toxic sterols. The majority of ARAF isolates contain alterations in the target enzyme and the mutated target showed reduced or no binding to the drugs [15]. While most mutations in ARAF isolates were single nucleotide substitutions in the target gene (cyp51A), mutations at other genes such as the cdr1B have also been reported. For example, in the United Kingdom the frequency of ARAF isolates without cyp51A mutations has been reported to be more than 50% [16].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Denning, D. W., Pleuvry, A., & Cole, D. C. (2013) · Medical Mycology · doi:10.3109/13693786.2012.738312 · Cited by 495
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der Lee, H. A., Klaassen, C. H., Melchers, W. J. G., & Verweij, P. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031801 · Cited by 427
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Fraczek, M. G., Bromley, M., Buied, A., Moore, C. B., Rajendran, R., Rautemaa, R., Ramage, G., Denning, D. W., & Bowyer, P. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt075 · Cited by 315
Research works printed but not linked: 3
- Van der Linden JWM, Arendrup MC, Verweij PE, SCARE network (2011) Prospective international surveillance of azole resistance in Aspergillus fumigatus: SCARE-Network. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sep 17–20; Chicago, IL. Abstract M-490. (SCARE-NETWORK).
- Krishnan-Natesan S, Swaminathan S, Cutright J, <etal>et al</etal>.. (2010) Antifungal susceptibility pattern of Aspergillus fumigatus isolated from clinical specimens in Detroit Medical Center (DMC): rising frequency of high MIC of azoles (2003–2006). In: The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sep 12–15; Boston, MA, USA.
- H Badali, 2013, Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp 51A gene in Iran, Mycoses
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Self-citationFusarium: Molecular Diversity and Intrinsic Drug Resistance
Al-Hatmi, A. M. S., Meis, J. F., & de Hoog, G. S. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005464 · Cited by 432
Self-citationAntifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
Verweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., et al. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.001 · Cited by 330
Self-citationClinical implications of globally emerging azole resistance in Aspergillus fumigatus
Meis, J. F., Chowdhary, A., Rhodes, J. L., Fisher, M. C., & Verweij, P. E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0460 · Cited by 308
Self-citationThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
Self-citationF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment
Chowdhary, A., Sharma, C., & Meis, J. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix210 · Cited by 262
Self-citationAzole Resistance in Aspergillus fumigatus: A Consequence of Antifungal Use in Agriculture?
Berger, S., El Chazli, Y., Babu, A. F., & Coste, A. T. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01024 · Cited by 256
Triazole Resistance in Aspergillus spp.: A Worldwide Problem?
Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., & Cuenca-Estrella, M. (2016) · Journal of Fungi · doi:10.3390/jof2030021 · Cited by 142
Verweij, P. E., Zhang, J., Debets, A. J. M., Meis, J. F., van de Veerdonk, F. L., Schoustra, S. E., Zwaan, B. J., & Melchers, W. J. G. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30138-4 · Cited by 140
Self-citationZhang, J., Snelders, E., Zwaan, B. J., Schoustra, S. E., Meis, J. F., van Dijk, K., Hagen, F., van der Beek, M. T., Kampinga, G. A., Zoll, J., et al. (2017) · mBio · doi:10.1128/mbio.00791-17 · Cited by 129
Self-citationNonrandom Distribution of Azole Resistance across the Global Population of Aspergillus fumigatus
Sewell, T. R., Zhu, J., Rhodes, J., Hagen, F., Meis, J. F., Fisher, M. C., & Jombart, T. (2019) · mBio · doi:10.1128/mbio.00392-19 · Cited by 109
Self-citationChronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
Hayes, G., & Novak-Frazer, L. (2016) · Journal of Fungi · doi:10.3390/jof2020018 · Cited by 77
Neubauer, M., Zhu, Z., Penka, M., Helmschrott, C., Wagener, N., & Wagener, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13167 · Cited by 76
Sewell, T. R., Zhang, Y., Brackin, A. P., Shelton, J. M. G., Rhodes, J., & Fisher, M. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00548-19 · Cited by 62
Naqvi, S. A. H., Farhan, M., Ahmad, M., Kiran, R., Shahbaz, M., Abbas, A., Hakim, F., Shabbir, M., Tan, Y. S., & Sathiya Seelan, J. S. (2025) · Archives of Microbiology · doi:10.1007/s00203-024-04219-6 · Cited by 61
Lescar, J., Meyer, I., Akshita, K., Srinivasaraghavan, K., Verma, C., Palous, M., Mazier, D., Datry, A., & Fekkar, A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku316 · Cited by 54
Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline?
Al-Hatmi, A., de Hoog, G. S., & Meis, J. F. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s180912 · Cited by 47
Self-citationIn vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris
Rudramurthy, S. M., Colley, T., Abdolrasouli, A., Ashman, J., Dhaliwal, M., Kaur, H., Armstrong-James, D., Strong, P., Rapeport, G., Schelenz, S., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz280 · Cited by 44
Walker, T. A., Lockhart, S. R., Beekmann, S. E., Polgreen, P. M., Santibanez, S., Mody, R. K., Beer, K. D., Chiller, T. M., & Jackson, B. R. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2401.170971 · Cited by 13
Zhou, X., Yang, G., Li, C., Yang, F., & Chang, X. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.957857 · Cited by 11
Impairing fluoride export of Aspergillus fumigatus mitigates its voriconazole resistance
Binder, J., Held, J., & Krappmann, S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.003 · Cited by 3
Metadata
- Authors
- Chowdhary, A., Kathuria, S., Xu, J., & Meis, J. F.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-24
- Volume
- 9
- Issue
- 10
- Pages
- e1003633
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2035017907
- Cited by
- 380
- References
- 31
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-11-14)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.